Patents Examined by Nelson B Mosley, II
  • Bi-specific monovalent diabodies that are capable of binding CD123 and CD3, and uses thereof
    Patent number: 9822181
    Abstract: The present invention is directed to sequence-optimized CD 123×CD3 bi-specific monovalent diabodies that are capable of simultaneous binding to CD 123 and CD3, and to the uses of such diabodies in the treatment of hematologic malignancies.
    Type: Grant
    Filed: August 20, 2014
    Date of Patent: November 21, 2017
    Assignee: MacroGenics, Inc.
    Inventors: Ezio Bonvini, Leslie S. Johnson, Ling Huang, Paul A. Moore, Gurunadh Reddy Chichili, Ralph Froman Alderson